RayzeBio (RayzeBio) Interest Coverage : N/A (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is RayzeBio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. RayzeBio's Operating Income for the three months ended in Sep. 2023 was $-21.65 Mil. RayzeBio's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. RayzeBio inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for RayzeBio's Interest Coverage or its related term are showing as below:

RYZB's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 156.65
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RayzeBio Interest Coverage Historical Data

The historical data trend for RayzeBio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

RayzeBio Interest Coverage Chart

RayzeBio Annual Data

Trend

Dec20

Dec21

Dec22

Interest Coverage

No Debt

N/A

RayzeBio Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23
Interest Coverage	Get a 7-Day Free Trial			No Debt	No Debt	N/A	N/A	N/A

Competitive Comparison of RayzeBio's Interest Coverage

For the Biotechnology subindustry, RayzeBio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RayzeBio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RayzeBio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where RayzeBio's Interest Coverage falls into.

RayzeBio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RayzeBio's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, RayzeBio's Interest Expense was $0.00 Mil. Its Operating Income was $-72.12 Mil. And its Long-Term Debt & Capital Lease Obligation was $9.43 Mil.

GuruFocus does not calculate RayzeBio's interest coverage with the available data.

RayzeBio's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the three months ended in Sep. 2023, RayzeBio's Interest Expense was $0.00 Mil. Its Operating Income was $-21.65 Mil. And its Long-Term Debt & Capital Lease Obligation was $8.46 Mil.

GuruFocus does not calculate RayzeBio's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

RayzeBio (NAS:RYZB) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

RayzeBio Interest Coverage Related Terms

Thank you for viewing the detailed overview of RayzeBio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

RayzeBio (RayzeBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121

Website

https://www.rayzebio.com

RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.

Executives

Hauwermeiren Timothy Van	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi	director	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush	officer: Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p.	10 percent owner	280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song	director, officer: President and Chief Executive	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran	officer: Chief Medical Officer	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p.	10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129